Journal of Thoracic Oncology Impact Factor Jumps Significantly

Friday, June 21, 2019

RFP Header-1.jpg

Contact:  Becky Bunn, MSc                                         
IASLC Interim Director of Communications and Director of Strategic Initiatives                                                   
Becky.Bunn@IASLC.org | 720-325-2946

Chris Martin
Cmartin@davidjamesgroup.com  | 630.670.2745

Release Date: June 21, 2019        

Journal of Thoracic Oncology Impact Factor Jumps Significantly
Growth Represents the Quality of Research and the Speed to Publication for the IASLC’s Official Journal

DENVER – The International Association for the Study of Lung Cancer (IASLC) announces a significant jump in the 2018 Impact Factor of the Journal of Thoracic Oncology (JTO) to 12.460, up from 10.336 in 2017. The JTO, the official journal of the IASLC, now ranks 10th out of all oncology journals and 3rd out of all respiratory system journals.

Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the impact factor for 2018 is the number of times articles published in 2016 and 2017 are cited in 2018.The higher the impact factor, the more highly ranked the journal.Journal citation reports are issued by Clarivate Analytics.

The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists and basic scientists with a special interest in thoracic oncology.

“With this new impact factor, JTO is now among the top 10 Oncology Journals and a leading journal in thoracic oncology,” said Dr Alex Adjei, Editor-in-Chief.“This achievement is a testament to the strong editorial team which helps to handle manuscripts quickly, the IASLC that supports JTO’s mission and the support of the thoracic oncology clinical and research community”

The JTO continues to have a quick turn-around time of 9.3 days to initial decision, and an average of 12.5 days for revisions, a fast track category, publish on acceptance (within 16 days) and promotion of select articles via social media and press releases. Authors can promote their own research by utilizing Elsevier enhancements such as Sharelink.

To submit a manuscript or to learn more about the JTO, please visit jto.org. Once there, readers can peruse current in-press articles, collections of lung cancer staging and pathology articles and the freely available Editor’s Choice articles. The full contents of the JTO are a free benefit for IASLC members.

An academic journal’s impact factor is a measure of the frequency with which the average article has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the JTO

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

###


About the Author

Chris Martin, Vice President, Public Relations